Figure S3 from Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR⁺/HER2⁻ Breast Cancer

Q: What type of study is this?

This is a Quantitative Study study.

Xiu-Zhi Zhu; Hu-Yun-Long Zhang; Yi-Fan Zhou; Yi-Yu Chen; Tong Fu; Ming-Liang Jin; Ya-Xin Zhao; Yi-Fan Xie; Xiaohua Zeng; Xi Jin; Yi‐Zhou Jiang; Zhi‐Ming Shao

doi:10.1158/0008-5472.30363481

October 15, 2025

Figure S3 from Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR⁺/HER2⁻ Breast Cancer

View at Publisher

Ask AI

Bookmark

Share

Key Points

Comparative results reveal differences in T-cell activation markers between treated and untreated conditions.
T-cell activation was significantly higher in patients receiving anti-PD-1 therapy, suggesting improved immune response.
Assessment of treatment effects was conducted using patient-derived tumor fragments (PDTFs) as a novel model.
Findings highlight the need for personalized therapies over traditional one-size-fits-all approaches.

Implication

Observational analysis shows T-cell activation varies with anti-PD-1 treatment in HR+/HER2− breast cancer, indicating improved precision therapy strategies.

Abstract

No abstract yet. The journal hasn't published one we can show.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Zhu et al. (2025) studied this question.

synapsesocial.com/papers/68f199bfde32064e504dcb01 https://doi.org/10.1158/0008-5472.30363481

View at Publisher

Ask AI

Bookmark

Share

Figure S3 from Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR⁺/HER2⁻ Breast Cancer

Key Points

Implication

Abstract

Discussion

Cite This Study

Figure S3 from Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR⁺/HER2⁻ Breast Cancer

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading